China has become the first nation to approve Roche’s crovalimab, a paroxysmal nocturnal hemoglobinuria (PNH) treatment. Unlike AstraZeneca’s infused treatments Soliris and Ultomiris, crovalimab is administered subcutaneously. Developed by Roche’s subsidiary Chugai Pharmaceutical, crovalimab is a humanized complement inhibitor C5 monoclonal antibody. The approval from China’s National Medical Products Administration (NMPA) allows its use in patients aged 12 and above who haven’t undergone complement inhibitor therapy before.
Crovalimab, a genetically engineered anti-C5 antibody developed using Chugai’s Recycling Antibody technology, is designed to bind to its target...
